QUESTIONS AND OBJECTIVES OF ALL-MB 2015 STUDY
1. Will the new risk group stratification (especially of T-ALL) to improve overall and
event-free survival?
2. Will the new protocol is effective and feasible in patients older than 15 years, and
especially in young adults?
3. Whether the intermittent dexamethasone administration in induction will result in a
decrease in toxicity and mortality without loss of efficacy?
4. Whether the methylprednisolone administration as basic glucocorticoids during induction,
consolidation and maintenance therapy will lead to decrease of severe infections and
early mortality rate, improve survival and therapy compliance in adolescents and young
adults with B-precursor ALL?
5. Whether the administration of Bortezomib in patients with B-precursor ALL with initial
WBC≥100,000/µl will improve treatment outcome?
6. Whether the administration of Idarubicin instead Daunorubicin in low-risk T-ALL patients
and two-phase induction in intermediate-risk T-ALL patients will reduce relapse rate and
improve survival?
Phase:
N/A
Details
Lead Sponsor:
Federal Research Institute of Pediatric Hematology, Oncology and Immunology